romidepsin (FK228)

a bicyclic depsipeptide and a potent histone deacetylase inhibitor from Chromobacterium violaceum; structure in first source

Also Known As:

FK228; FR901228; FR 901228; FR-901228; L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-; istodax

Networked: 505 relevant articles (47 outcomes, 154 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bates, Susan E: 29 articles (01/2021 - 03/2002)
2.	Prince, H Miles: 16 articles (12/2017 - 11/2009)
3.	Piekarz, Richard L: 16 articles (07/2015 - 03/2002)
4.	Figg, William D: 12 articles (11/2016 - 03/2002)
5.	Robey, Robert W: 11 articles (01/2021 - 03/2002)
6.	Wang, Hwa-Chain Robert: 9 articles (01/2021 - 11/2009)
7.	Sokol, Lubomir: 9 articles (10/2019 - 02/2012)
8.	Coiffier, Bertrand: 9 articles (12/2017 - 02/2012)
9.	Horwitz, Steven: 8 articles (01/2022 - 02/2012)
10.	Pro, Barbara: 8 articles (12/2017 - 02/2012)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2016 - "Promising results have emerged from early clinical studies, supporting the potential for romidepsin combination regimens to constitute safe and effective treatments for cancer." 01/01/2014 - "Our in vitro study suggested that combination of FK228 and RXM may be helpful for enhancing tumor killing effects. " 01/01/2021 - "Further studies on FK228 analogues may positively contribute to the availability of potent agents in tumor treatment." 10/15/2020 - "Data from the ETCTN-9008 trial led to changes in the romidepsin labeling to reflect starting dose adjustment for patients with cancer and moderate and severe hepatic impairment, with no adjustment for mild hepatic impairment." 10/15/2020 - "Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study."
2.	T-Cell Lymphoma (Lymphoma, T Cell) 08/01/2013 - "These initial results observed with single-agent romidepsin provide a foundation for exploring combination strategies and demonstrates proof-of-principle that other such drugs with similar mechanisms of action may be effective in T-cell lymphoma. " 02/01/2018 - "Prior studies have shown that romidepsin is capable of inducing durable responses with manageable toxicities in patients with mature T-cell lymphomas. " 05/16/2013 - "Gene expression analysis of samples obtained from patients with CTCL enrolled on the NCI1312 phase 2 study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathway by romidepsin. " 11/10/2009 - "On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. " 11/01/2009 - "To date, over 120 patients with T-cell lymphoma have been treated on a multi-institutional phase II trial of romidepsin. "
3.	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 02/20/2012 - "The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). " 01/01/2022 - "Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)." 11/01/2017 - "Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study." 10/01/2017 - "Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials." 01/01/2017 - "Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial."
4.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 10/10/2010 - "The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL). " 12/01/2013 - "Based on two large Phase II studies, the US FDA approved intravenous romidepsin for patients with relapsed/refractory cutaneous T-cell lymphomas. " 10/01/2012 - "Phase 1 and 2 trials evaluating the efficacy and safety of romidepsin were reviewed with a specific focus on its use in cutaneous T-cell lymphoma. " 10/10/2010 - "Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma." 12/01/2019 - "Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study."
5.	Mycosis Fungoides 07/01/2012 - "Observations were made during a phase II clinical trial sponsored by the National Cancer Institute (NCI-1312) examining the efficacy of romidepsin for patients with relapsed, refractory or advanced CTCL, stage IB-IVA mycosis fungoides (MF) or Sézary syndrome. " 11/02/2016 - "We presented a patient with a history of stage II CLL, referred to dermatology for treatment of new-onset of mycosis fungoides (MF), who was treated with romidepsin over seven months. " 01/01/2019 - "Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome." 01/01/2019 - "Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma." 11/02/2016 - "Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides."

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	romidepsin (FK228)
3.	Depsipeptides
4.	Histone Deacetylases (Histone Deacetylase)
5.	10-propargyl-10-deazaaminopterin
6.	Vorinostat
7.	Gemcitabine
8.	Bortezomib (Velcade)
9.	Decitabine
10.	Lenalidomide (CC 5013)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Hematopoietic Stem Cell Transplantation
4.	Cell Transplantation
5.	Stem Cell Transplantation